Low-Grade Endometrial Stromal Sarcoma

Low-Grade Endometrial Stromal Sarcoma

Article
Women's Health
Diseases & Conditions
+1
Contributed byKrish Tangella MD, MBAOct 30, 2018

What are the other Names for this Condition? (Also known as/Synonyms)

  • LG-ESS (Low-Grade Endometrial Stromal Sarcoma)
  • LGESS (Low-Grade Endometrial Stromal Sarcoma)
  • Endometrial Stromal Myosis (not recommended)

What is Low-Grade Endometrial Stromal Sarcoma? (Definition/Background Information)

  • Low-Grade Endometrial Stromal Sarcoma (LG-ESS) is a type of endometrial stromal sarcoma, which is a malignant tumor of the uterus. The tumor is composed of malignant cells that are similar to the proliferative phase of endometrial stromal cells (which represents the tissue between the endometrial glands)
  • Low-Grade Endometrial Stromal Sarcoma is mostly present in adult women, and both pre- and post- menopausal women may be affected. The tumors are known to be caused by genetic mutations and chromosomal aberrations
  • The signs and symptoms of Low-Grade Endometrial Stromal Sarcoma include unusual vaginal bleeding, abdominal pain, and sensation of pressure in the pelvic area. The complications are dependent upon the stage of the cancer and the method of treatment employed. Advanced stage tumors are observed to metastasize to the lung and ovary
  • Treatment for the malignancy is mainly through surgery and supplementary treatment measures that include radiation therapy and chemotherapy. The prognosis of Low-Grade Endometrial Stromal Sarcoma mostly depends on the cancer stage, and is generally good for tumors diagnosed in the initial stages

Who gets Low-Grade Endometrial Stromal Sarcoma? (Age and Sex Distribution)

  • Low-Grade Endometrial Stromal Sarcoma may be present in adult women of any age; women of a wide age group may be affected
  • LG-ESS is seen in slightly younger women (mean age 52 years), when compared to other sarcomas affecting the uterus
  • There is no geographical, racial, or ethnic preference observed
  • Low-Grade Endometrial Stromal Sarcomas form less than 1% of the malignant tumors observed in the uterine corpus, and so, it is a very rare tumor type. But, LG-ESS is among the most common mesenchymal malignancy affecting the uterus

What are the Risk Factors for Low-Grade Endometrial Stromal Sarcoma? (Predisposing Factors)

The following are the potential risk factors for Low-Grade Endometrial Stromal Sarcoma:

  • Tamoxifen therapy
  • Long-term estrogen therapy (stimulation)
  • Radiation to the pelvic region
  • Polycystic ovarian syndrome (PCOS)

It is important to note that having a risk factor does not mean that one will get the condition. A risk factor increases one’s chances of getting a condition compared to an individual without the risk factors. Some risk factors are more important than others.

Also, not having a risk factor does not mean that an individual will not get the condition. It is always important to discuss the effect of risk factors with your healthcare provider.

What are the Causes of Low-Grade Endometrial Stromal Sarcoma? (Etiology)

The cause of development of Low-Grade Endometrial Stromal Sarcoma is related to genetic abnormalities. The tumor is known to originate from the endometrial stroma.

Currently, studies indicate defects in the following genes:

  • JAZF1-SUZ12(JJAZ1) fusion gene due to t(7;17)(p21;q15) is seen in half the number of cases
  • EPC1-PHF1 is the next frequently observed gene abnormality
  • Other abnormalities seen include:
    • t(6;7)(p21;p15), t(6;10;10)(p21;q22;p11), and t(1;6)(p34;p21)
    • All these (above) are known to cause PHF1-JAZF1, EPC1-PHF1, and MEAF6-PHF1 gene fusion defects

What are the Signs and Symptoms of Low-Grade Endometrial Stromal Sarcoma?

Some women may not show any signs and symptoms. In others, the signs and symptoms of Low-Grade Endometrial Stromal Sarcoma may include:

  • The presence of a solitary, small or large tumor; the majority are between 5-10 cm in size
  • Most tumors have poorly-defined boundaries; though, some are well-defined and can cause diagnostic challenges
  • Sensation of pelvic mass or enlarged uterus
  • Most of the tumors are located intramurally (i.e., found within the uterine walls)
  • Involvement of the adnexa (parts around the uterus) is seen in 1 in 10 cases
  • In some cases, polypoid tumors are observed
  • Heavy or abnormal bleeding from the uterus and abdominal pain are both common symptoms in women with LG-ESS
  • Signs and symptoms may also occur from large-sized tumors causing compression of adjoining uterine structures including frequent urination and lower back pain
  • Tumor necrosis and hemorrhage is observed
  • The tumors can invade into the myometrium and vascular system of lymph nodes (lymphovascular spaces)
  • Pain during sexual intercourse
  • Weight loss, weakness, and lethargy

How is Low-Grade Endometrial Stromal Sarcoma Diagnosed?

The diagnosis of Low-Grade Endometrial Stromal Sarcoma may involve:

  • Complete physical examination with thorough evaluation of medical history
  • Ultrasound scan of the pelvis: It is a noninvasive procedure that uses high frequency sound waves to produce real-time images
  • Abdominal and pelvic CT scan: It is a noninvasive procedure that provides more details of soft tissues, blood vessels, and internal organs
  • Pelvic MRI scan: It is a noninvasive medical test that uses a powerful magnetic field to produce images of soft tissues, bones, organs, and all other internal structures of the abdomen and pelvis
  • Blood tests that include:
    • Complete blood count (CBC) to detect the cause of anemia
    • Determination of estrogen/progesterone levels in blood
  • Hysteroscopy: This procedure involves placing a probe through the cervix to examine the cavity of the uterus. This exam is helpful in detecting submucosal tumors
  • Hysterosalpingography: It is usually performed in individuals with infertility. In this procedure, the structure of the uterus and fallopian tubes are studied by using a dye and X-ray images
  • Needle biopsy of tumor: A needle biopsy may not be helpful, because one may not be able to visualize the different morphological areas of the tumor. Hence, a needle biopsy as a diagnostic tool has certain limitations, and an open surgical biopsy is preferred
  • Open biopsy of tumor: A tissue biopsy is performed and sent to a laboratory for a pathological examination, who examines the biopsy under a microscope. After putting together clinical findings, special studies on tissues (if needed) and with microscope findings, the pathologist arrives at a definitive diagnosis

A differential diagnosis to eliminate the following tumor types is considered, before arriving at a definitive diagnosis of LG-ESS:

  • Adenomyosis
  • Cellular endometrial polyp
  • Cellular leiomyoma
  • Low-grade mullerian-adenosarcoma
  • The following tumors may be confused with metastatic endometrial stromal sarcoma occurring outside the genital tract (known as extragenital ESS):
    • Gastrointestinal stromal tumor (GIST)
    • Hemangiopericytoma
    • Lymphangiomyomatosis
    • Mesenchymal cystic hamartoma of the lung

Note:

  • A dilation and curettage (D&C) of the uterus or an endometrial biopsy is not helpful in establishing a proper classification of ES tumors such as low-grade and high-grade endometrial stromal sarcoma
  • Extensive sampling during a pathological examination can help diagnose endometrial stromal sarcoma (ESS) and exclude other kinds of malignancies

Many clinical conditions may have similar signs and symptoms. Your healthcare provider may perform additional tests to rule out other clinical conditions to arrive at a definitive diagnosis.

What are the possible Complications of Low-Grade Endometrial Stromal Sarcoma?

The possible complications of Low-Grade Endometrial Stromal Sarcoma include:

  • Stress and anxiety due to cancer of the uterus
  • Infertility
  • Heavy and prolonged menstrual bleeding may result in anemia
  • Polypoid tumors may undergo mechanical injury, such as torsion or twisting, which can result in excruciating pain
  • Such polyp-shaped tumors are known to cause cervical prolapse, in some cases
  • Some tumors may grow to large sizes, and even grow out of the uterus affecting adjoining reproductive organs
  • Metastasis: Spread of tumor to lung or ovary at the time of diagnosis; lymph node metastasis is seen in 3 out of 10 cases
  • The cancer can spread in any direction, even regionally; they can cause gastrointestinal tract or urinary tract signs and symptoms
  • Recurrence of the tumor due to its partial or incomplete surgical removal
  • Side effects of chemotherapy (such as toxicity) and radiation
  • Sexual dysfunction can take place as a side effect of surgery, chemotherapy, or radiation therapy

How is Low-Grade Endometrial Stromal Sarcoma Treated?

Once a diagnosis of cancer of the uterus has been made, the extent to which the tumor has spread is assessed. This is called staging.

Following is the staging protocol for uterine cancer, according to the American Joint Committee on Cancer (AJCC), updated July 2016:

Stage I uterine cancer: The cancer is found in the uterus only. Stage I is divided into stages IA and IB, based on how far the cancer has spread.

  • Stage IA: The cancer is in the endometrium only or less than halfway through the myometrium (muscle layer of the uterus).
  • Stage IB: The cancer has spread halfway or more into the myometrium.

Stage II uterine cancer: The cancer has spread into connective tissue of the cervix, but has not spread outside the uterus.

Stage III uterine cancer: The cancer has spread beyond the uterus and cervix, but has not spread beyond the pelvis. Stage III is divided into stages IIIA, IIIB, and IIIC, based on how far the cancer has spread within the pelvis.

  • Stage IIIA: The cancer has spread to the outer layer of the uterus and/or to the fallopian tubes, ovaries, and ligaments of the uterus.
  • Stage IIIB: The cancer has spread to the vagina and/or to the parametrium (connective tissue and fat around the uterus).
  • Stage IIIC: The cancer has spread to lymph nodes in the pelvis and/or around the aorta (largest artery in the body, which carries blood away from the heart).

Stage IV uterine cancer: The cancer has spread beyond the pelvis. Stage IV is divided into stages IVA and IVB, based on how far the cancer has spread.

  • Stage IVA: The cancer has spread to the bladder and/or bowel wall.
  • Stage IVB: The cancer has spread to other parts of the body beyond the pelvis, including the abdomen and/or lymph nodes in the groin.

(Source: Stages of Uterine Cancer, July 2016, provided by the National Cancer Institute at the National Institutes of Health; U.S. Department of Health and Human Services)

The following treatment measures may be considered for Low-Grade Endometrial Stromal Sarcoma:

Surgery: In younger women, who have only early-stage disease, appropriate surgical treatment with ovarian conservation may be an option.

  • Hysterectomy: A hysterectomy, or removal of the uterus, is the most common treatment procedure for localized (non-metastasized) cancer. In this procedure, the uterus and cervix are removed. This is done by making an incision on the abdomen (termed abdominal hysterectomy), or through the vagina (termed vaginal hysterectomy), or by using a laparoscope (termed laparoscopic hysterectomy). Surgery is performed under general or epidural anesthesia, though the ability to have children is lost. Complications, such as bleeding, infection, or damage to the urinary tract, or the intestinal system may occur in rare cases
  • Radical hysterectomy: A radical hysterectomy, removal of the uterus and tissues surrounding it, may be performed. But, this is typically more suited for tumors that have spread beyond the uterus. The uterus, cervix, the upper part of the vagina and tissues, next to the uterus are removed. Additionally, some pelvic lymph nodes may also be surgically taken out. The surgery is performed under anesthesia and may be carried out, via an incision made on the abdomen or by using laparoscopy. With this invasive procedure, the ability to have children is lost. Rarely, complications such as bleeding, infection, or damage to the urinary tract or the intestinal system, may occur. Removal of lymph nodes may lead to swelling of legs (lymphedema)
  • Pelvic exenteration: The uterus, tissues surrounding the uterus, cervix, pelvic lymph nodes, and the upper part of the vagina, are removed. In addition, depending on the tumor spread, the remainder of the vagina, the bladder, rectum, and a part of the colon, may also be removed. Recovery from this surgery takes a long period
  • Arterial embolization may be used to provide temporary relief from the symptoms, and reduce blood loss during a surgical procedure
  • Post-operative care is important: One must maintain minimum activity levels, until the surgical wound heals

Chemotherapy:

  • Medications are used to kill the tumor cells, which may be given as oral pills or injected into veins
  • A combination of chemotherapy medications may be used

Radiation therapy:

  • This procedure uses high-energy beams to kill the cancer cells
  • These beams may be delivered from outside the body (external beam radiation therapy) or the radioactive material maybe placed inside the vagina or the uterus (internal radiation therapy or brachytherapy)

Hormone therapy:

  • Hormonal therapy is a medical treatment used for women with advanced Endometrial Stromal Sarcomas that have metastasized beyond the uterus. It can also help in preventing or reducing the risk of recurrences
  • The treatment options include taking the following medications that affect the hormone levels in the body:
    • Synthetic progestin: Synthetic progestin, a type of hormone progesterone, may help prevent the development and progression of endometrial cancer cells
    • Luteinizing hormone (LH): Also called lutropin, this hormone therapy drug helps lower an individual’s estrogen level in the body, or decrease the body’s ability to use the available estrogen. Endometrial cancer cells rely on estrogen (the primary female sex hormone) to proliferate, and thus, administering LH drugs may cause the cancer cells to die out

In addition to traditional adjuvant therapies, the following techniques are being investigated for cancers of the uterus, in general:

  • Immunotherapy aims to stimulate the patient’s immune system to recognize and destroy the cancer cells. It includes:
    • Antigen vaccines
    • DNA vaccines
    • Viral therapy
    • Gene therapy
  • Currently, clinical trials on adjuvant chemotherapy and combinational chemotherapy, as secondary treatment to hysterectomy, are showing promising results on reducing the risk of relapse

Many patients with metastatic or locally advanced tumors may be referred for clinical trials for experimental treatment options.

Once treatment is complete, it is recommended that the patient schedule regular check-ups (and for a long duration of time), based on the recommendation of the specialist treating them. 

How can Low-Grade Endometrial Stromal Sarcoma be Prevented?

Current medical research has not established a method of preventing Low-Grade Endometrial Stromal Sarcoma. However, the following general factors may be considered to reduce the risk for tumor development:

  • Address any condition causing hormonal imbalance in the body
  • Maintain weight through proper diet modification and physical exercises, if you are overweight/obese
  • Avoid alcohol consumption or limit its intake
  • Have a balanced diet that is not high in meat and low in vegetables; a balanced diet can also help avoid any mineral or vitamin deficiencies in the body
  • Regular medical screening at periodic intervals with blood tests, radiological scans, and physical examinations are mandatory, due to risk of recurrence and metastasizing potential of the tumor. Often several years of active vigilance may be necessary

What is the Prognosis of Low-Grade Endometrial Stromal Sarcoma? (Outcomes/Resolutions)

  • In many cases, the prognosis of Low-Grade Endometrial Stromal Sarcoma is generally good for early-stage tumors. In higher (late) stage tumors, the survival rates decrease and the prognosis is guarded
  • Hence, the stage of the tumor is the most important factor dictating prognosis of LG-ESS tumors. The 5-year survival rate is 90% for stage I and II tumors, but reduces to 50% for stage III and IV tumors
  • In general, the prognosis depends upon a set of several (other) factors that include:
    • The size of the tumor and the extent of its invasion: Individuals with small-sized tumors fare better than those with large-sized tumors
    • Stage of cancer: With lower-stage tumors, when the tumor is confined to site of origin, the prognosis is usually excellent with appropriate therapy. In higher-stage tumors, such as tumors with metastasis, the prognosis is poor
    • Cell growth rate of the cancer: A high mitotic count, more than 5 per 10 high-power fields, is an unfavorable prognostic factor
    • Overall health of the individual: Individuals with overall excellent health have better prognosis compared with those with poor health
    • Age of the individual: Older individuals (over 50 years) generally have poorer prognosis than younger individuals
    • Ethnicity of the individual: Generally, dark-skinned women have a poorer prognosis than fair-skinned individuals
    • CD10 negative or low expression of CD10 on immunohistochemical studies is associated with poorer prognosis
    • Lack of estrogen and progesterone receptors are independent prognostic factors for poor survival
    • Individuals with bulky disease have a poorer prognosis
    • Involvement of the regional lymph nodes, which can adversely affect the prognosis. Individuals with nodal metastasis have generally poorer outcomes
    • Involvement of vital organs may complicate the condition
    • The surgical respectability of the tumor (meaning, if the tumor can be removed completely): A lack of primary surgery (due to various reasons) is a poor prognostic indicator
    • Whether the tumor is occurring for the first time, or is a recurrent tumor. Recurring tumors have worse prognosis compared to tumors that do not recur
    • Response to treatment: Tumors that respond to treatment have better prognosis compared to tumors that do not respond to treatment
    • Progression of the condition makes the outcome worse
  • An early diagnosis and prompt treatment of the tumor generally yields better outcomes than a late diagnosis and delayed treatment
  • The combination chemotherapy drugs used, may have some severe side effects (like cardio-toxicity). This chiefly impacts the elderly adults, or those who are already affected by other medical conditions. Individuals, who tolerate chemotherapy sessions better, generally have better outcomes

Additional and Relevant Useful Information for Low-Grade Endometrial Stromal Sarcoma:

  • Removal of the uterus will cause the regular menstrual bleeding to stop. This also means that a woman may not have children after uterus removal; though, sexual intercourse is still possible 
  • Hysterectomy is a surgical procedure characterized by the surgical removal of the uterus

The following link will help you understand hysterectomy surgical procedure:

http://www.dovemed.com/common-procedures/procedures-surgical/hysterectomy-abdominal-with-salpingo-oophorectomy/

Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!